<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936256</url>
  </required_header>
  <id_info>
    <org_study_id>CB-20-001</org_study_id>
    <nct_id>NCT04936256</nct_id>
  </id_info>
  <brief_title>Evaluation of Binocular Visual Acuity and Refractive Stability in the Alcon Clareon Intraocular Lens</brief_title>
  <official_title>Evaluation of Binocular Visual Acuity and Refractive Stability in the Alcon Clareon Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gainesville Eye Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sengi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gainesville Eye Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate refractive stability (spherical equivalent change ≤ 0.50D from&#xD;
      1-month to 3-months).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-arm, evaluator masked clinical evaluation study of refractive&#xD;
      stability, after successful bilateral cataract surgery. Subjects will be assessed&#xD;
      pre-operatively, operatively and at 1 month and 3 months post-operatively. Clinical&#xD;
      evaluations will include measurement of bilateral visual acuity, manifest refraction, and&#xD;
      defocus curve.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Refractive stability</measure>
    <time_frame>3 months</time_frame>
    <description>Refractive stability (spherical equivalent change ≤ 0.50D from 1-month to 3-months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binocular uncorrected distance visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Binocular uncorrected distance visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binocular uncorrected intermediate visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Binocular uncorrected intermediate visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binocular best-corrected distance visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Binocular best-corrected distance visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binocular best-corrected intermediate visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Binocular best-corrected intermediate visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binocular defocus curve</measure>
    <time_frame>3 months</time_frame>
    <description>Binocular defocus curve</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Bilateral implantation of the Clareon monofocal IOL</arm_group_label>
    <description>Clareon monofocal intraocular lens (IOL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clareon</intervention_name>
    <description>Clareon monofocal intraocular lens (IOL)</description>
    <arm_group_label>Bilateral implantation of the Clareon monofocal IOL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects ≥50 years of age presenting for cataract surgery who are appropriate candidates&#xD;
        for intraocular lens implantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects are eligible for the study if they meet the following criteria:&#xD;
&#xD;
        Note: Ocular criteria must be met in both eyes.&#xD;
&#xD;
          -  Presenting for uncomplicated bilateral cataract surgery and have an interest in an IOL&#xD;
             option&#xD;
&#xD;
          -  Gender: Males and Females.&#xD;
&#xD;
          -  Age: 50 or older&#xD;
&#xD;
          -  Willing and able to provide written informed consent for participation in the study&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits and other study procedures.&#xD;
&#xD;
          -  Have good ocular health, with no pathology that compromises visual acuity (outside of&#xD;
             residual refractive error and cataract)&#xD;
&#xD;
          -  Potential postoperative visual acuity of (20/25 Snellen) or better in both eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        If any of the following exclusion criteria are applicable to the subject or either eye, the&#xD;
        subject should not be enrolled in the study.&#xD;
&#xD;
          -  Irregular astigmatism (e.g. keratoconus)&#xD;
&#xD;
          -  Corneal pathology (e.g. scar, dystrophy, pterygium, severe dry eye)&#xD;
&#xD;
          -  Previous radial keratotomy, corneal refractive surgery or other corneal surgery (e.g.&#xD;
             corneal transplant, DSAEK, lamellar keratoplasty)&#xD;
&#xD;
          -  Previous anterior or posterior chamber surgery (e.g., vitrectomy, laser iridotomy)&#xD;
&#xD;
          -  Diabetic retinopathy&#xD;
&#xD;
          -  Macular pathology (e.g. ARMD, ERM)&#xD;
&#xD;
          -  History of retinal detachment&#xD;
&#xD;
          -  Any patient based on Barrett toric calculator that will have ≥ 0.75D residual&#xD;
             astigmatism if Clareon® non-toric IOL is implanted&#xD;
&#xD;
          -  Subjects who have an acute or chronic disease or illness that would confound the&#xD;
             results of this investigation (e.g., immunocompromised, connective tissue disease,&#xD;
             clinically significant atopic disease, diabetes, and any other such disease or&#xD;
             illness), that are known to affect postoperative visual acuity&#xD;
&#xD;
          -  Participation in any investigational drug or device trial within the previous 30 days&#xD;
             prior to the start date of this trial (or currently participating)&#xD;
&#xD;
        The principal investigator reserves the right to declare a patient ineligible or&#xD;
        non-evaluable based on medical evidence that indicates they are unsuitable for the trial.&#xD;
&#xD;
        Pregnancy has a known effect on the stability of refractions and visual acuity. As such,&#xD;
        subjects who become pregnant during the study will not be discontinued but their data may&#xD;
        be excluded from analyses of effectiveness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Clayton Blehm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gainesville Eye Associates</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MaryAnn Thomas</last_name>
    <phone>7705324444</phone>
    <phone_ext>44</phone_ext>
    <email>mthomas@gainesvilleeye.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clayton Blehm, MD</last_name>
    <phone>7705324444</phone>
    <email>claytonblehm@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gainesville Eye Associates</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MaryAnn Thomas</last_name>
      <phone>770-532-4444</phone>
      <email>mthomas@gainesvilleeye.com</email>
    </contact>
    <contact_backup>
      <last_name>Clayton G Blehm, MD</last_name>
      <phone>770-532-4444</phone>
      <email>claytonblehm@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monofocal IOL</keyword>
  <keyword>Clareon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

